Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 4/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PARG | Q86W56 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6022484 | 0.94 | ALDH1A1 (0.62) | ALDH1A1TSHRMAPK1KDM4ETAAR1 | |
| SCHEMBL6022490 | 0.85 | PARG (0.46) | ALDH1A1TSHRMAPK1KDM4ETAAR1 | |
| SCHEMBL6023756 | 0.84 | MAPK1 (0.47) | ALDH1A1TSHRMAPK1HSD17B10LMNA | |
| SCHEMBL6023282 | 0.81 | ALOX15 (0.52) | ALDH1A1TSHRMAPK1KDM4ETAAR1 | |
| SCHEMBL6023202 | 0.80 | PARG (0.52) | ALDH1A1TSHRKDM4ETAAR1HSD17B10 | |
| SCHEMBL6022431 | 0.79 | BRD1 (0.61) | MAPK1LMNAPKMTP53PARG | |
| SCHEMBL6022506 | 0.79 | MEN1 (0.56) | — | |
| SCHEMBL6022256 | 0.78 | MAPK1 (0.48) | ALDH1A1TSHRMAPK1KDM4EPKM | |
| SCHEMBL6022426 | 0.78 | PARG (0.52) | ALDH1A1KDM4EPKMGAAPARG | |
| SCHEMBL6022151 | 0.78 | POLB (0.64) | ALDH1A1PKMTP53GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7009052-B2 | Sulfonamide derivatives | WARNER LAMBERT COMPANY LLC (US) | 2006-03-07 | — | — | US | claimed |
| US-20050004367-A1 | Sulfonamide derivatives | DU DANIEL Y (US) | 2005-01-06 | — | — | US | claimed |
| US-7009052-B2 | Sulfonamide derivatives | WARNER LAMBERT COMPANY LLC (US) | 2006-03-07 | — | — | US | disclosed |
| US-20050004367-A1 | Sulfonamide derivatives | DU DANIEL Y (US) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004367-A1 | Sulfonamide derivatives | AR, SULT2A1, SHBG | ALDH1A1 841/4885TSHR 660/4885MAPK1 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.